NANOVIBRONIX: POSITIVE RESULTS FROM INDEPENENT, DOUBLE-BLIND TRIAL OF PAINSHIELD

 NanoVibronix, Inc., (NASDAQ: NAOV), a healthcare device company that produces the UroShield® and PainShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced positive results from a randomized, double-blind study conducted at Birmingham Orthopedic and Sports Specialists in Birmingham, Alabama.

Clinicians at Birmingham Orthopedic and Sports Specialists recently conducted a randomized, double-blind study to evaluate the safety and effectiveness of the NanoVibronix PainShield. Patients in the study were being treated by an orthopedic surgeon for lateral epicondylitis, more commonly known as tennis elbow, a swelling or tearing of the tendons in the arm. It is characterized by a pain or ache on the outside of the arm where the forearm meets the elbow. All patients in the study had symptoms of pain and point tenderness at the beginning of the study and had been following customary treatment guidance, which failed to provide pain relief. Conversely, at the conclusion of the study, 91% of the patients in the PainShield treatment group had complete or partial resolution of symptoms. Patients used PainShield in conjunction with over-the-counter medication, as needed, but without the benefit of opioid-based prescription medication.

Brian Murphy, CEO of Nanovibronix, stated, “Results of the Birmingham study further reinforce that PainShield is safe, easy-to-use and highly effective in treating soft tissue pain. Patients in the study who wore our device reported marked reduction in pain and when combined with over-the-counter, anti-inflammatory medications, those same patients reported a complete resolution of symptoms within 10 days.”

https://finance.yahoo.com/news/nanovibronix-announces-positive-results-indepenent-130600003.html